London, UK - Despite inducing only a modest drop in blood pressure (BP), the ACE inhibitor ramipril (Altace® - Monarch Pharmaceuticals) caused a significant reduction in cardiovascular death, MI, or ...

Preclinical and clinical data suggest that angiotensin-converting-enzyme inhibitors (ACEIs) may reduce the risk for ischemic events independent of the drugs' blood pressure-lowering effects. This is ...

Background: The Heart Outcomes Prevention Evaluation (HOPE), a Canadian-led, multicentre, randomized controlled trial, demonstrated the effectiveness of the ACE inhibitor ramipril in the secondary ...

Please provide your email address to receive an email when new articles are posted on . Patients with type 2 diabetes may have another therapeutic option to improve vascular dysfunction and markers of ...

Inhibition of angiotensin-converting enzyme (ACE) with ramipril as an adjunct to standard medical therapy increases both the maximum and the pain-free walking time of patients with peripheral artery ...

Angiotensin-converting-enzyme (ACE) inhibitors were developed for the treatment of hypertension. Subsequently they became indicated for several cardiovascular and renal conditions. ACE inhibitors play ...

People being prescribed ramipril could be at risk of suffering a serious kidney-related side effect that may need be monitored by a doctor. Ramipril is commonly prescribed to treat heart failure and ...